Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18566979 | 0.98 | L3MBTL1 (0.41) | L3MBTL1APOBEC3ACTDSP1APOBEC3GTDP1 | |
| SCHEMBL18352085 | 0.93 | HCAR2 (0.42) | L3MBTL1APOBEC3ACTDSP1APOBEC3GTDP1 | |
| SCHEMBL18352055 | 0.92 | HCAR2 (0.41) | L3MBTL1APOBEC3ACTDSP1APOBEC3GTDP1 | |
| SCHEMBL18352146 | 0.92 | HCAR2 (0.44) | L3MBTL1APOBEC3ACTDSP1APOBEC3GTDP1 | |
| SCHEMBL18566998 | 0.91 | L3MBTL1 (0.41) | L3MBTL1APOBEC3ACTDSP1APOBEC3GTDP1 | |
| SCHEMBL18352082 | 0.90 | HCAR2 (0.42) | L3MBTL1APOBEC3ACTDSP1APOBEC3GTDP1 | |
| SCHEMBL18352147 | 0.88 | HCAR2 (0.41) | L3MBTL1APOBEC3ACTDSP1APOBEC3GTDP1 | |
| SCHEMBL18566997 | 0.82 | TDP1 (0.39) | L3MBTL1TDP1ALDH1A1MAPTKDM4E | |
| SCHEMBL18566996 | 0.82 | CYP1A2 (0.39) | L3MBTL1TDP1ATMLMNAALDH1A1 | |
| SCHEMBL18566990 | 0.82 | L3MBTL1 (0.46) | L3MBTL1LMNAALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9597306-B1 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-03-21 | — | — | US | disclosed |
| US-9597306-B1 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170056358-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056358-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | L3MBTL1 4164/4885APOBEC3A 3740/4885CTDSP1 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.